Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA

Serena Marchetti, Jan H.M. Schellens(Utrecht University), Olaf van Tellingen(Dutch Cancer Society), Roberto Mazzanti(Azienda Ospedaliero-Universitaria Careggi), Monique van Eijndhoven(Amsterdam UMC Location Vrije Universiteit Amsterdam), Jos H. Beijnen(The Netherlands Cancer Institute), Dick Pluim
Investigational New Drugs
January 12, 2013
10.1007/s10637-013-9923-1
Cited by 26

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884